标题
Targeting Oncogenic Mutant p53 for Cancer Therapy
作者
关键词
-
出版物
Frontiers in Oncology
Volume 5, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2015-12-21
DOI
10.3389/fonc.2015.00288
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of pesticide chemicals on the activity of metabolic enzymes: focus on thiocarbamates
- (2018) Cécile Mathieu et al. Expert Opinion on Drug Metabolism & Toxicology
- A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
- (2015) S. Ramalingam et al. ANNALS OF ONCOLOGY
- Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53
- (2015) Shengliang Zhang et al. CANCER RESEARCH
- Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
- (2015) Masatsugu Hiraki et al. CHEMISTRY & BIOLOGY
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
- (2015) E. M. Alexandrova et al. NATURE
- A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
- (2015) H. Nechushtan et al. ONCOLOGIST
- p53 orchestrates between normal differentiation and cancer
- (2015) Noa Rivlin et al. SEMINARS IN CANCER BIOLOGY
- Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells
- (2015) Yong Weon Yi et al. Oncotarget
- Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism
- (2015) Xin Yu et al. Oncotarget
- Chemopreventive Effects of the p53-Modulating Agents CP-31398 and Prima-1 in Tobacco Carcinogen-Induced Lung Tumorigenesis in A/J Mice
- (2015) Chinthalapally V. Rao et al. NEOPLASIA
- Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
- (2014) M N Saha et al. BRITISH JOURNAL OF CANCER
- Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations
- (2014) L. Martin et al. CANCER RESEARCH
- p53 as a target for the treatment of cancer
- (2014) Michael J. Duffy et al. CANCER TREATMENT REVIEWS
- A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
- (2014) Komal Jhaveri et al. Clinical Breast Cancer
- Mutant p53 reactivation by small molecules makes its way to the clinic
- (2014) Vladimir J.N. Bykov et al. FEBS LETTERS
- Limiting the power of p53 through the ubiquitin proteasome pathway
- (2014) Vinod Pant et al. GENES & DEVELOPMENT
- Molecular Analysis, Pathogenic Mechanisms, and Readthrough Therapy on a Large Cohort of Kabuki Syndrome Patients
- (2014) Lucia Micale et al. HUMAN MUTATION
- A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
- (2014) Lipika Goyal et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes
- (2014) Fabio Efficace et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
- (2014) Noemi Reguart et al. LUNG CANCER
- Metabolic control of YAP and TAZ by the mevalonate pathway
- (2014) Giovanni Sorrentino et al. NATURE CELL BIOLOGY
- The cellular thermal shift assay for evaluating drug target interactions in cells
- (2014) Rozbeh Jafari et al. Nature Protocols
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase
- (2014) Wensheng Yan et al. PLoS One
- Targeting p53 for Novel Anticancer Therapy
- (2014) Zhen Wang et al. Translational Oncology
- A degradative detour for mutant TP53
- (2013) Helin Vakifahmetoglu-Norberg et al. Autophagy
- Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
- (2013) M. Yanada et al. BLOOD
- Identification of potential synthetic lethal genes to p53 using a computational biology approach
- (2013) Xiaosheng Wang et al. BMC Medical Genomics
- Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells
- (2013) Ameya Paranjpe et al. CARCINOGENESIS
- Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro
- (2013) M. Burmakin et al. CLINICAL CANCER RESEARCH
- Chaperone-mediated autophagy degrades mutant p53
- (2013) H. Vakifahmetoglu-Norberg et al. GENES & DEVELOPMENT
- Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer
- (2013) Changhoon Yoo et al. INVESTIGATIONAL NEW DRUGS
- Delivery materials for siRNA therapeutics
- (2013) Rosemary Kanasty et al. NATURE MATERIALS
- Small molecule induced reactivation of mutant p53 in cancer cells
- (2013) Xiangrui Liu et al. NUCLEIC ACIDS RESEARCH
- Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells
- (2013) S Masciarelli et al. ONCOGENE
- Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells
- (2013) Hai-Bin Zhu et al. World Journal of Surgical Oncology
- Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
- (2013) Christopher D. Wassman et al. Nature Communications
- Allele-Specific p53 Mutant Reactivation
- (2012) Xin Yu et al. CANCER CELL
- Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
- (2012) William A. Freed-Pastor et al. CELL
- The substitutions G245C and G245D in the Zn2+-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain
- (2012) S.S. Pintus et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- p53 mutations in cancer
- (2012) Patricia A. J. Muller et al. NATURE CELL BIOLOGY
- Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
- (2012) W Yan et al. ONCOGENE
- Synthetic lethality: exploiting the addiction of cancer to DNA repair
- (2011) M. Shaheen et al. BLOOD
- Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers
- (2011) Shouji Shimoyama CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13
- (2011) Junli Liu et al. CELL
- Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
- (2011) Rosa Puca et al. CELL CYCLE
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- (2011) D Li et al. CELL DEATH AND DIFFERENTIATION
- PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
- (2011) R. Zandi et al. CLINICAL CANCER RESEARCH
- Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
- (2011) F. R. Kona et al. CURRENT CANCER DRUG TARGETS
- Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function
- (2011) Ofer Margalit et al. INTERNATIONAL JOURNAL OF CANCER
- Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression
- (2011) Wensheng Yan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
- (2011) D. Li et al. MOLECULAR CANCER RESEARCH
- Arsenic Exposure and Toxicology: A Historical Perspective
- (2011) Michael F. Hughes et al. TOXICOLOGICAL SCIENCES
- HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression
- (2010) Jacqueline Kessler et al. BMC CANCER
- Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies
- (2010) I Goldstein et al. CANCER GENE THERAPY
- USP10 Regulates p53 Localization and Stability by Deubiquitinating p53
- (2010) Jian Yuan et al. CELL
- Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
- (2010) Carolyn Y. Zhao et al. CELL CYCLE
- Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits
- (2010) C. R. M. Lammens et al. Familial Cancer
- Cys-141 glutathionylation of human p53: Studies using specific polyclonal antibodies in cancer samples and cell lines
- (2010) Mohd. A. Yusuf et al. FREE RADICAL BIOLOGY AND MEDICINE
- SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53
- (2010) Mark Demma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP
- (2010) Jia Wang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells
- (2010) HaiBin Zhu et al. MEDICAL ONCOLOGY
- Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
- (2010) Célia Floquet et al. NUCLEIC ACIDS RESEARCH
- A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent
- (2009) Yali Kong et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Mutant p53 mediates survival of breast cancer cells
- (2009) L Y Lim et al. BRITISH JOURNAL OF CANCER
- Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
- (2009) Vera V. Grinkevich et al. CANCER CELL
- PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
- (2009) Jeremy M.R. Lambert et al. CANCER CELL
- Cooperation of tumor-derived HBx mutants and p53-249ser mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line
- (2009) Weidong Jiang et al. INTERNATIONAL JOURNAL OF CANCER
- PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein
- (2009) Hyder INTERNATIONAL JOURNAL OF ONCOLOGY
- Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
- (2009) J M R Lambert et al. ONCOGENE
- A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
- (2009) S. Sur et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Target identification using drug affinity responsive target stability (DARTS)
- (2009) B. Lomenick et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
- (2009) M. Olivier et al. Cold Spring Harbor Perspectives in Biology
- Structural Biology of the Tumor Suppressor p53
- (2008) Andreas C. Joerger et al. Annual Review of Biochemistry
- The mitochondrial p53 pathway
- (2008) Angelina V. Vaseva et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
- A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
- (2008) L Weinmann et al. CELL DEATH AND DIFFERENTIATION
- The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
- (2008) T. Terzian et al. GENES & DEVELOPMENT
- Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells
- (2008) Hongyan Gu et al. MOLECULAR CANCER THERAPEUTICS
- Mutant p53 targeting by the low molecular weight compound STIMA-1
- (2008) Nicole Zache et al. Molecular Oncology
- Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
- (2008) J. E. Kravchenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
- (2008) F. M. Boeckler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started